Lantern Pharma (LTRN) Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Q4 2025 Financials::

General and Administrative Expenses: $1.5 million (down from $1.6 million in Q4 2024)

R&D Expenses: $2.7 million (down from $4.3 million in Q4 2024)

Net Loss: $4.1 million ($0.36 per share), improved from a net loss of $5.9 million ($0.54 per share) in Q4 2024.

Full Year 2025 Financials::

R&D Expenses: $11.5 million (down from $16.1 million in 2024)

General and Administrative Expenses: $6.5 million (up from $6.1 million in 2024)

Net Loss: $17.1 million ($1.57 per share), improved from $20.8 million ($1.93 per share) in 2024.

Cash Position: Approximately $10.1 million as of December 31, 2025, expected to fund operations until mid-2026.

2Strategic Updates and Business Highlights

Clinical Development::

Achieved clinical validation for multiple programs, including LP-300 and LP-184, with significant milestones in their respective trials.

LP-300's Phase II HARMONIC trial is addressing a critical unmet need in non-small cell lung cancer among never smokers, with promising early results.

LP-184 Phase I results showed a 48% clinical benefit rate in heavily pretreated cancer patients, validating the synthetic lethal hypothesis.

New Initiatives::

Established an AI center of excellence in India to enhance the RADR platform's capabilities.

Received FDA IND clearance for a pediatric CNS cancer trial through Starlight Therapeutics, with multiple rare pediatric disease designations that could lead to significant future value.

3Forward Guidance and Outlook

Upcoming Type C meeting with the FDA in May 2026 to discuss protocol amendments for LP-300.

Plans to initiate new clinical trials for LP-184 in bladder cancer and triple-negative breast cancer, subject to funding.

Anticipated launch of the withZeta AI platform at the AACR conference, aiming for commercial partnerships and revenue generation.

Continued focus on advancing clinical programs while seeking additional funding through grants and partnerships.

4Bad News, Challenges, or Points of Concern

Funding Needs:: The company will require substantial additional funding in the near future to support ongoing operations and clinical trials.

Market Competition:: The landscape for precision oncology and AI-driven drug development is becoming increasingly competitive, which may pose challenges.

Disinformation Issues:: The CEO addressed false claims regarding his departure, indicating potential reputational risks and stock price manipulation.

5Notable Q&A Insights

The management emphasized the transformative potential of AI in drug development, highlighting the unique capabilities of their RADR platform and withZeta AI.

Clarifications were provided regarding the strategic direction of LP-300 and LP-184, with a focus on specific patient populations and mechanistic insights driving future trials.

The potential for monetizing FDA priority review vouchers associated with rare pediatric disease designations was discussed as a significant value driver. Overall, Lantern Pharma demonstrated a commitment to advancing its clinical pipeline while leveraging AI technology, despite facing funding challenges and competitive pressures in the biotech landscape.